Introduction
Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer type worldwide, with >500,000 new cases of HNSCC diagnosed worldwide every year.
Approximately 60% of HNSCC are diagnosed at an advanced stage, and the prognosis is poor, despite the numerous forms of treatment available (1, 2) . In recent decades, the 5-year survival rate has improved (3) . Although the development of new therapies and advanced examination techniques has prolonged the life of the patients, HNSCC is considered difficult to treat, with the exception of early stage tumors (3) . In order to increase patient quality of life, a strategy for the early detection of HNSCC is urgently required. Several biomarkers have been associated with the diagnosis and prognosis of HNSCC, but few have demonstrated adequate clinical efficacy (4) .
Programmed death-ligand 1 (PD-L1) is an immune co-stimulatory molecule that belongs to the B7-H gene family (5) . It is expressed on many tumor cell types and the surface of immune cells, including B cells, T cells, myeloid dendritic cells and macrophages (6) . PD-L1 serves an important role in regulating cellular immunity. PD-L1 combined with programmed cell death protein 1 (PD-1) inhibits the migration and proliferation of T cells, as well as the secretion of cytotoxic mediators, thus limiting its antitumor effects on tumor cells (7, 8) . Therefore, anti-PD-L1 monoclonal antibodies (αPD-L1) are effective in oncotherapy, and antitumor immunity may be enhanced by inhibiting the expression of PD-L1 (9) . Anti-PD-L1 monoclonal antibodies have shown considerable promise in the treatment of melanoma, renal cell carcinoma and non-small cell lung cancer (10) . The PD-L1/PD-1 axis has gained increasing attention in cancer immunotherapy and immunopathogenesis (11) . The majority of research has focused on antitumor immunity, particularly in T cells. However, tumor-intrinsic PD-L1 signals have not been extensively investigated (12) . Recently, the regulation of tumor cell proliferation by PD-L1 family members has gained increasing attention; it has been revealed that PD-L1 participates in epithelial-mesenchymal transition (EMT) regulation (13, 14) , and is closely associate with cell cycle progression (15, 16) and the expression of proliferation marker Ki-67 in human breast cancer (16) . Based on these previous findings, it was speculated that tumor-intrinsic PD-L1 signaling may have broad biological effects, which require further investigation.
In the present study, the function of PD-L1 in HNSCC was investigated. Immunohistochemical analysis was used to detect PD-L1 expression in HNSCC tissues. Next, it was demonstrated that PD-L1 promoted HNSCC cell proliferation PD-L1 promotes head and neck squamous cell carcinoma cell growth through mTOR signaling in vitro and in vivo. In addition, the potential mechanisms underlying the PD-L1-mediated increase in HNSCC cell proliferation were explored. The current research aimed to provide experimental evidence for the use of PD-L1 as a therapeutic target in HNSCC. For the colony formation assay, cells were seeded into 6-well plates (200 cells/well) and incubated in complete medium for 12 days at 37˚C. The 6-well plates were washed with PBS and stained with 0.1% crystal violet at room temperature for 15 min. Colonies which consisted of >50 cells were counted under an Olympus IX51 microscope (Olympus Corp.).
Materials and methods

Patient selection and tissue microarray (TMA
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Total RNA was isolated with TRIzol™ reagent (Thermo Fisher Scientific, Inc.). RNA (1 µg) was reverse transcribed using the Super RT Reverse Transcriptase reagent kit (Beijing CoWin Biotech Co., Ltd., Beijing, China) according to the manufacturer's instructions. qPCR was conducted in a 25 µl reaction system, using the 7500 Fast Real-Time PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.) and amplified with transcript-specific primers and SYBR ® -Green Master Mix (Thermo Fisher Scientific, Inc.), according to the manufacturer's instructions. Relative gene expression was calculated using the 2 -ΔΔCq method (18) , with GAPDH as the internal control. PD-L1 (cat. no. HQP008443) and GAPDH (cat. no. HQP006940) primers were purchased from GeneCopoeia, Inc. (Rockville, MD, USA). The primer sequences were as follows: PD-L1 forward, 5'-TAG AAT TCA TGA GGA TAT TTG CTG TCT T-3' and reverse, 5'-TAG GAT CCT TAC GTC TCC TCC AAA TGT G-3'; GAPDH forward, 5'-TGA CTT CAA CAG CGA CAC CCA-3' and reverse, 5'-CAC CCT GTT GCT GTA GCC AAA-3. LI-COR Biosciences, Lincoln, NE, USA) at room temperature for 1 h, the membranes were scanned by an Odyssey infrared imaging system (LI-COR Biosciences).
Statistical analysis. All values are expressed as the mean ± standard deviation of three independent experimental repeats.
Statistical analyses were performed in SPSS 19.0 (SPSS, Inc., Chicago, IL, USA), using one-way analysis of variance with Tukey's post hoc test. P<0.05 was considered to indicate a statistically significant difference.
Results
PD-L1 expression in HNSCC.
In order to examine the expression of PD-L1 in HNSCC, NAT and normal tissues, TMAs of HNSCCs stained for PD-L1 were analyzed, and the CES of every clinical sample was measured. PD-L1 expression was compared and associated with clinical characteristics, including tumor grade and TNM staging. PD-L1 expression in tumor tissue was significantly higher than in normal tissue and NAT (P<0.01), with no significant difference in PD-L1 expression between normal tissue and NAT (P>0.05; Fig. 1A) . T-stage analysis revealed that although the expression of PD-L1 in normal tissue was significantly higher in T1 (P<0.01), T2 (P<0.05) and T4 (P<0.05), there was no statistical significance in PD-L1 expression in T3 (P>0.05; Fig. 1B) . It is likely that a larger number of samples are required to fully investigate the relationship between T-stage and PD-L1, as the sample sizes of T1 and T3 were insufficient, and the expected increase in PD-L1 expression with T stage progression was not observed. For the N-stage, representative images were presented in Fig. 1C . The CES of the PD-L1 protein expression revealed that there was no significant differences between the N-stages (P>0.05). As N-stage indicates regional lymph node metastasis, these results suggest that PD-L1 may have no relationship with the regional metastasis of HNSCC. Finally, the expression of PD-L1 among different tumor grades was compared respectively, demonstrating that an increased tumor grade was associated with increased PD-L1 expression (Fig. 1D) .
PD-L1 regulates the proliferation and colony formation in HNSCC cell lines in vitro.
To explore the function of PD-L1, stable PD-L1-overexpressing (PD-L1 over ), PD-L1 knockdown (PD-L1 RNAi ) and negative control cells (PD-L1 over NC , PD-L1 RNAi NC ) were generated, and the expression of PD-L1 was detected by RT-qPCR and western blotting. The stably transfected Cal-27 and FaDu cells were established and representative micrographs showed the immunofluorescence of GFP in cells (Fig. 2A) . It was demonstrated that the lentiviral transduction particles successfully altered PD-L1 protein (Fig. 2B) and gene (Fig. 2C) expression. PD-L1 RNAi HNSCC cell proliferation was significantly reduced, compared with its respective control group, with the PD-L1 over cells exhibiting the highest rate of proliferation (Fig. 3A) . Furthermore, the EdU proliferation assay revealed a similar trend, in which the PD-L1-overexpressing cells exhibited the highest red fluorescence (Fig. 3B) . Furthermore, the colony forming ability of PD-L1-overexpressing cells was remarkably increased compared with the PD-L1 over NC group, and colony numbers in the PD-L1 knockdown group were significantly reduced, compared with the PD-L1 RNAi NC group (Fig. 3C) .
PD-L1 upregulates mTOR signaling in HNSCC cell lines.
To investigate the potential mechanism by which PD-L1 promoted cell growth in HNSCC cells, the expression levels of proteins associated with mTOR signaling and cell proliferation were detected by western blotting (Fig. 4A) . Compared with their corresponding control groups, p-P70S6K T389 and p-Akt S473 expression was significantly increased on the PD-L1 over group, but significantly decreased in the PD-L1
RNAi group (Fig. 4B) .
Effect of PD-L1 expression on tumor growth in vivo.
To validate whether the expression of PD-L1 affected tumor growth in vivo, Cal-27 cells were used to establish a xenograft mouse model. At the 12 week end point, the tumor growth curve (Fig. 5A) showed that the tumor volume in the Cal-27-PD-L1 over group was significantly larger than the control group (P<0.01), and the tumor volume in the PD-L1
RNAi group was the smallest (P<0.05). The tumors were removed and measured on week 12 (Fig. 5B) , and the average volume was calculated (Fig. 5C) . These results demonstrated that PD-L1 accelerated tumor growth, suggesting an important role for PD-L1 in regulating the tumor cell growth in vivo. No significant differences in animal weight were detected (Fig. 5D) .
PD-L1 enhances the sensitivity of HNSCC cells to mTOR inhibitor in vitro.
As PD-L1 upregulated the expression of proteins involved in mTOR signaling, the effects of mTOR inhibitor rapamycin were investigated. Cellular proliferation was significantly inhibited in the PD-L1 over group following treatment with mTOR inhibitor. PD-L1
over Cal-27 cells were the most sensitive to rapamycin in the four groups, and the PD-L1
RNAi tumor cells were the most tolerant to rapamycin-mediated proliferation inhibition (Fig. 6A-C) . The result obtained in Cal-27 and FaDu cells were consistent. Although there was no significant statistical difference between PD-L1 RNAi and PD-L1 RNAi NC groups in FaDu cells, it was still indicated that PD-L1 exerted some regulatory action on tumor cell proliferation, and mTOR inhibitor was effective in preventing the PD-L1-driven proliferative effects. As presented in Fig. 4 , PD-L1 knockdown reduced the activation of mTORC1 and mTORC2. In response to rapamycin treatment, p-P70S6K T389 expression was markedly suppressed, and p-P70S6KT 389 could mediate a negative feedback loop on phosphoinositide 3-kinase (PI3K)/Akt which was de-repressed by rapamycin, and elevated the level of p-Akt S473 ( Fig. 7A and B) . The proportion of p-P70S6K T389 appeared the most markedly decreased in PD-L1 over+RP cells, compared with PD-L1 over cells; , which increased, was more than PD-L1 RNAi+RP (Fig. 7B) , further indicating that PD-L1 may have promoted cell growth through mTOR signaling upregulation.
Discussion
PD-1 is predominantly expressed in activated T/B cells, where its function is to suppress immune cell activation via a physiological self-stabilization mechanism (19) . Overactivation of T/B cells lead to autoimmune diseases, and thus PD-1 has a protective role (19, 20) . In the tumor microenvironment, infiltrating T cells overexpress PD-1, and PD-L1 and PD-L2 are highly expressed by tumor cells; the ligation of PD-1/PD-L1 inhibits T cell activation (21) . T cell migration and proliferation is inhibited, as well as the secretion of perforin and granzymes by cytotoxic T cells, which greatly limits their killing effects on tumor cells (22) . Blocking the binding of PD-1 to PD-L1 would likely prevent immune escape, enhance antitumor immunity and inhibit tumor progression. At present, the efficacy of PD-1-targeted therapy is very low as a monotherapy, with an overall response rate of 20-50% in cases with multiple tumors (23, 24) . However, it has been suggested that combining PD-1-targeted therapy with other therapeutic methods may significantly augment the curative effect and the overall response rate (25) . Therefore, the combination of PD-1/PD-L1 inhibition with other therapies requires further research.
As a novel target of immunotherapy, tumor-expressed PD-L1 mediates cancer immunopathogenesis by negatively regulating T cells (26) . However, increasing evidence has suggested that PD-L1 has critical functions in promoting tumor formation and development, without relying on the immune checkpoint (15, 27) . Previous studies have confirmed PD-L1 mRNA is upregulated in a wide variety of tumors, such as pulmonary adenocarcinoma, breast cancer and squamous lung cancer (13, 28, 29) . A previous study reported that PD-L1 protein expression was increased in squamous cell carcinoma (SCC) of the head and neck, esophagus and lung (30) . In addition, PD-1 expression is upregulated in response to proinflammatory cytokines IFN-γ, TNF-α and IL-1β, and PD-L1 blockade by a monoclonal antibody efficiently augments the effects of adaptive T cell immunotherapy in a murine model of PD-L1-transfected SCC, and inhibits the growth of de novo induced PD-L1 + SCC (21, 30) . In the present study, TMAs were obtained to detect PD-L1 expression characteristics in HNSCC. PD-L1 expression was significantly higher in tumor tissue, compared with NAT and normal tissue. Of note, the expression of PD-L1 progressively increased along with the increase of the tumor grades. These results suggested that PD-L1 was associated with HNSCC tumorigenesis. Consistent with the results of the present study, Strome et al (31) also reported that PD-L1 protein was upregulated in SCC and highly expressed in 66% (16 of 24) of freshly isolated SCC samples of the head and neck (31) . However, the relationship between PD-L1 expression and tumor TNM staging remains unclear in certain reports, as well as its relationship with regional lymph node metastasis (32, 33) . In the present study, the results revealed that PD-L1 expression was not significantly different between T/N stages. PD-L1/PD-1 plays an important role in directly regulating the tumor microenvironment, and considering the complicated effects of PD-L1/PD-1 in the tumor and tumor microenvironment (9) , it is difficult to illuminate the relationship between PD-L1 and T/N stages. Additionally, the small sample size may have had an impact on the results. Hence, further investigation with a larger number of samples is required.
In addition, the role of PD-L1 as a non-immune checkpoint was demonstrated, which may be a potential therapeutic target in HNSCC. The majority of studies focusing on PD-L1 have predominantly focused on immunity, particularly in T cells (11, 24, 31) . Although it has been reported that blocking PD-L1 affects tumor cell proliferation (12, 27, 34) , it was uncertain whether PD-L1 inhibition suppresses tumor growth in HNSCC. Through the generation of stable PD-L1-overexp ressing (PD-L1 over ), and PD-L1 knockdown (PD-L1 RNAi ) cell lines, the present study demonstrated that PD-L1 promoted tumor growth in vitro and in vivo. In addition, compared with the control group, PD-L1
RNAi HNSCC cell proliferation decreased, even in the rapamycin-treated RNAi group. Francisco et al (35) reported that PD-L1 mediates the development of regulatory T cells via downregulation of the mTOR pathway, coupled with the upregulation of phosphatase and tensin homolog (PTEN). In addition, it has been reported that blocking PD-L1 suppresses mTOR activity (27, 34) . Our preliminary experiments confirmed that PD-L1 had no significant effects on the expression of key proteins involved in multiple signaling pathways, such as signal transducer and activator of transcription, mitogen-activated protein kinase and nuclear factor-κB. Hence, it was concluded that PD-L1 may have exerted bi-directional effects in regulating the mTOR pathway, although the exact mechanism remains unclear in HNSCC.
The PI3K/Akt/mTOR signaling pathway has critical functions in both solid tumors and hematological malignancies (36) . mTOR regulates cell growth, motility, and metabolism; this signaling cascade is frequently upregulated in cancer due to loss of the tumor suppressor PTEN (37) . Glycogen synthase kinase-3 (GSK-3) also interacts with and affects the function of downstream components of the PI3K/Akt/mTOR signaling network (38) . Bertacchini et al (39) reported that dual inhibition of PI3K/mTOR signaling resensitizes resistant cancer cells to chemotherapy (39) . mTOR contains two complexes, mTORC1 and mTORC2. p-P70S6K T389 is the downstream effector of mTORC1, and p-Akt S473 is the downstream effector of mTORC2. mTORC1 and mTORC2 exert important influences on the growth and survival of tumor cells (40, 41) . In the present study, it was demonstrated that PD-L1 increased p-P70S6K T389 and p-Akt S473 expression in HNSCC cell lines, and cells overexpressing PD-L1 proliferated faster than control cells. Thus, PD-L1 may have been capable of regulating both mTORC1 and mTORC2 expression. In addition, mTORC1 inhibitor suppressed p-P70S6K T389 expression and prevented the PD-L1-mediated increase in proliferation. Cell proliferation inhibition rate of the PD-L1 over cells was the highest in the four groups following treatment with mTOR inhibitor, and PD-L1
RNAi cells were the most resistance to rapamycin-mediated proliferation inhibition. In addition, p-Akt S473 expression was increased in the of PD-L1 over+RP cells, compared with the PD-L1 RNAi+RP cells, this may be the combined effect of p-P70S6K T389 -mediated negative feedback loop on phosphoinositide 3-kinase (PI3K)/Akt which was de-repressed by rapamycin and low PD-L1-mediated restraint of p-Akt
S473
. Therefore, further study is required to understand the mutual influence of both these factors.
Accumulating evidence has revealed that the curative effect of anti-PD-L1 treatment is superior to anti-cytotoxic T-lymphocyte protein 4 therapy (42, 43) . It has been speculated that anti-PD-L1 may not only prevent PD-L1-mediated immune escape, but may also restrain PD-L1-mediated carcinogenesis. This may also be the reason why anti-PD-L1 therapy has been reported to be more effective than immunotherapy in tumors (42) . In addition, it suggests that tumor intrinsic PD-L1 signals have an antitumor effect.
In conclusion, the present study revealed that the expression of PD-L1 was significantly higher in HNSCC compared with normal tissues or cell lines, and the expression of PD-L1 increased as the tumor grade progressed. Further, PD-L1 promoted HNSCC cell proliferation both in vitro and in vivo. PD-L1 depletion led to a downregulation of mTOR signaling, and mTOR inhibitor prevented the PD-L1-mediated proliferative effect. These findings increased the current understanding of PD-L1-mediated carcinogenesis in HNSCC, and may be conducive in discovering novel therapeutic targets in HNSCC.
